(Finance) – Il Menarini Group announced the first preliminary results for the 2023 financial year, closed with a consolidated turnover of 4.375 billion of euros, in growth of 5.3% compared to 2022. A turnover achieved largely abroad (79%) and in the Pharmaceutical sector, which lost 96% of revenues, while Diagnostics accounts for approximately 3%. EBITDA is estimated overall at 340-350 million of Euro.
The Florentine company headed by the Aleotti family is present in 140 countries in the mworld with subsidiaries, distributors and licensees and counting 17,800 employeesof which 49.5% are women.
These are some of the results and numbers presented this evening by Lucia Aleottishareholder and member of the Menarini Board, together with the CEO, Elcin Barker Ergun.
Europe is the heart of the Group: in 2023 they were produced in these factories 609 million packs out of a total of 833 million units, for a total of 16.1 billion tablets.
The Group has 9 research centersmostly located in Europe, two in the USA (New York and Philadelphia) and one in Asia (Singapore).